Evidence map›Paper›PMID 41879095›Full record

Observational studyAIDS (London, England)2026

Risk of type 2 diabetes mellitus after treatment with direct-acting antivirals for hepatitis C virus in people with HIV.

Mathieu Chalouni, Jessie Torgersen, Christopher T Rentsch, Daniela K Van Santen, Inmaculada Jarrin, Marina B Klein, Jim Young, M John Gill, Rachel L Epstein, Benjamin Linas and 16 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in AIDS (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Mathieu ChalouniCAUSALab, Department of Epidemiology, Harvard T H Chan School of Public Health, Harvard University, Boston, MA.
Jessie TorgersenDepartment of Medicine, Perelman School of Medicine.
Christopher T RentschDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA; VA Connecticut Healthcare System, US Department of Veterans Affairs, West Haven, CT, USA.
Daniela K Van SantenCAUSALab, Department of Epidemiology, Harvard T H Chan School of Public Health, Harvard University, Boston, MA.
Inmaculada JarrinHospital General Universitario Gregorio Marañón, liSGM, Madrid, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
Marina B KleinDivision of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, McGill University Health Centre and Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
Jim YoungDivision of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, McGill University Health Centre and Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
M John GillSouthern Alberta Clinic and Department of Medicine, University of Calgary, Calgary, AB, Canada.
Rachel L EpsteinDepartment of Medicine, Section of Infectious Diseases, Boston Medical Center.
Benjamin LinasDepartment of Medicine, Section of Infectious Diseases, Boston Medical Center.
Robert ZangerleDepartment of Dermatology, Venereology, and Allergy, Medical University Innsbruck, Innsbruck, Austria.
Bernard SurialDepartment of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern.
Johannes NemethDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Giota TouloumiDepartment of Hygiene, Epidemiology, & Medical Statistics.
Antonios Papadopoulos4th Department of Internal Medicine, Attikon University General Hospital, Medical School, National & Kapodistrian University of Athens, Athens, Greece.
Linda WittkopUniversity of Bordeaux, INSERM, Bordeaux Population Health-U1219, CIC1401-EC, Bordeaux, France; SISTM, INRIA, Talence, France; CHU de Bordeaux, Bordeaux University Hospital, Service d'information médicale, INSERM, Bordeaux, France.
Marc Van Der ValkStichting hiv Monitoring.
Anders BoydStichting hiv Monitoring.
Antonella D'arminio MonforteIcona Foundation, Milan, Italy.
Massimo PuotiIcona Foundation, Milan, Italy.
Roger W LoganCAUSALab, Department of Epidemiology, Harvard T H Chan School of Public Health, Harvard University, Boston, MA.
Sophia M ReinCAUSALab, Department of Epidemiology, Harvard T H Chan School of Public Health, Harvard University, Boston, MA.
José M MiroInfectious Diseases Service, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain; Reial Academia de Medicina de Catalunya (RAMC), Barcelona, Spain.
Juan BerenguerHospital General Universitario Gregorio Marañón, liSGM, Madrid, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
Miguel A HernánCAUSALab, Department of Epidemiology, Harvard T H Chan School of Public Health, Harvard University, Boston, MA.
Sara LodiCAUSALab, Department of Epidemiology, Harvard T H Chan School of Public Health, Harvard University, Boston, MA.

Funding

Dynamic Strategies for the clinical management of HIV diseaseR37AI102634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI MIGUEL HERNAN · 2018 to 2026
$5.3M
NIAID NIH HHS R37 AI102634
6 · The paper itself

Abstract

objectiveTo compare the 3-year risk of type 2 diabetes mellitus (T2DM) in people with HIV-HCV after direct-acting antiviral (DAA) initiation and in people with HIV mono-infection.

designAn observational study of two collaborations of cohorts from Europe and North America.

methodsWe matched individuals with evidence of ongoing HIV-HCV co-infection eligible to receive DAA (HepCAUSAL Collaboration) with individuals with HIV mono-infection (HIV-CAUSAL Collaboration) on cohort, calendar month, and probability of HCV diagnosis. We estimated the 3-year post-DAA T2DM risk had all HIV-HCV co-infection individuals initiated DAA using inverse probability weighting and compared it with the risk people with HIV mono-infection in subgroups defined by number of diabetes risk factors (0, 1-2, or ≥3).

results34 135 people with HIV-HCV co-infection and 68 720 with HIV mono-infection were included. The difference in 3-year risk of T2DM for people with HIV-HCV after DAA and people with HIV mono-infection was 0.8% (95% confidence interval: -0.6, 5.8) in the subgroup with no risk factor, -0.4% (-1.5, 1.2) in the subgroup with 1-2 risk factors, and -1.7% (-4.7, 1.5) in the subgroup with ≥3 risk factors.

conclusionsThe estimated post-DAA risk of T2DM in people was similar to the risk in people with HIV mono-infection, though estimates were imprecise. These results suggest diabetes monitoring and prevention strategies should be the same for people with HIV who received DAA for HCV treatment as for people with HIV mono-infection, and based on risk factors.

Indexed as

Antiviral AgentsDiabetes Mellitus, Type 2Hepatitis C, ChronicHIV InfectionsCoinfectionEuropeHumansNorth AmericaRisk AssessmentRisk FactorsAntiviral Agentsdirect-acting antiviralsHIV-HCV co-infectionHIV mono-infectiontype 2 diabetes mellitus

Identifiers

PMID41879095
PMCPMC13111791

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.